MAR – Page 5 – Alligator Bioscience

2020-04-27

Regulatory

Alligator Bioscience presents promising interim Phase I data for its bispecific drug candidate ATOR-1015 at AACR

Lund, Sweden, April 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents the status of the o ...

2020-04-23

Regulatory

Stronger focus on clinical projects "The focusing of our operations protects the company’s liquidity, but is also part of our long-term ...

2020-04-07

Regulatory

Lund, Sweden, 7 April 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today that the company has decided to increase its fo ...

2020-04-01

Regulatory

Lund, Sweden, 1 April 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today a temporary halt in the recruitment of new pati ...

2020-02-12

Regulatory

"2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project ...

2019-10-24

Regulatory

"We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 su ...

2019-08-20

Regulatory

Lund, Sweden, August 20, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that a license agreement has been reached wi ...

2019-07-31

Regulatory

Lund, Sweden, July 31, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that it has regained exclusive, worldwide righ ...

2019-05-15

Regulatory

Lund, Sweden, May 15, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Janssen Biotech, Inc. (Janssen) will prese ...